There have been tremendous strides made within the medical space thanks to 3D printing. We have seen bioprinting transform the way in which we view the future of organ transplantation, while the 3D printing of prostheses has changed the lives of hundreds of people worldwide. One other area, which has recently begun to show promise, is that of 3D printed custom medication.
There have been several groups working on technology capable of printing out customized medication. However, one recent group of researchers from the University of Central Lancashire (UCLan) seem to be leading the way, and doing so in a rather affordable way. The team from the School of Pharmacy and Biomedical Science, led by Dr Mohamed Albed Alhnan, have created a special type of 3D printer filament consisting of drugs. The drug-polymer filament, as they call it, is used in place of traditional thermoplastic filaments such as PLA and ABS. The filament, can be used in almost any desktop 3D printer on the market which uses typical 1.75mm filament, and is harmless to the human body.
The researchers have been testing this application on a MakerBot Replicator 3D printer, fabricating theophylline tablets, sized how they choose.
“3-D printing has been embraced by lots of different industries but we have shown how this technology can be harnessed to improve medical care, providing low-cost, personally tailored medicines for patients,” stated Dr Mohamed Albed Alhnan.
Imagine waking up in the morning, hitting a button on your computer, and within minutes have your daily dose of life-saving medication. This is where we are likely headed according to researchers. The ability to print these drugs on affordable desktop machines could lead to cheaper rates on medication, as well as a convenience which would be a godsend to those patients unable to regularly leave their homes.
“Thanks to this technology, the invented system can provide medical institutions with a new option and maintain dosage form properties while accurately adjusting the dose with simple software order, something that was considered before to be costly and required experienced staff and dedicated facilities,” said Alhan. “Eventually, we hope to see that units can be kept at home for patients who continuously need to change their daily dose.”
According to UCLan, this technology could possibly be used by pharmaceutical companies as early as 2019, and may eventually be available in people’s homes within the next decade. Certainly there will be some regulatory hurdles to overcome before this happens, but such technology would enable patients to ensure exact dosages without being constricted to the most popular dosage sizes via pre-produced pills.
Check out the video below, provided by UCLan, of a MakerBot machine 3D printing a theophylline tablet.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
Print Services
Upload your 3D Models and get them printed quickly and efficiently.
You May Also Like
U.S. Marines Save Hundreds of Thousands with 3D Printed Antenna Mast
Recently, I wrote about an article by Col. Michael Mai, Chief of the US Army Working Capital Fund, in which he argued that the Army is “mispricing readiness” and that...
3D Printing News Briefs, February 14, 2026: Project Call, Maritime Construction, Prosthetics, & More
Happy Valentine’s Day! We’re starting this weekend’s News Briefs off with a Project Call award, and then moving on to a business growth program. We’ll end with research in underwater...
Stratasys Partners With Defense Prime Heavyweights to Qualify SAF PA12 for Industrial 3D Printing
Perhaps the most valuable lesson that the additive manufacturing (AM) industry has learned in its technical maturation era over the last five years or so is that you can’t really...
Machina Labs Secures $124 Million at a Pivotal Moment for Defense Manufacturing
Machina Labs has raised $124 million in funding. Investors include Woven Capital, Lockheed Martin Ventures, Balerion Space Ventures, and Strategic Development Fund (SDF). Machina describes itself as “software-defined production infrastructure,”...
























